三友医疗(688085) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥120,657,457.36, representing a 57.30% increase compared to the same period last year[3]. - Net profit attributable to shareholders was ¥6,894,445.53, showing a significant increase of 104.53% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥4,501,943.38, reflecting a substantial increase of 675.10% compared to the previous year[3]. - The net profit attributable to shareholders for the year-to-date period is -87.07 million, impacted by the nationwide implementation of bulk procurement for high-value spinal consumables starting from Q1 2023, leading to a revenue decline[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period is -94.50 million, also affected by the bulk procurement policy and the inclusion of Implanet in the consolidation scope[8]. - The net profit for Q3 2024 is CNY 8,190,332.77, a significant decrease from CNY 75,220,211.77 in the same period last year, representing a decline of approximately 89.1%[20]. - Operating profit for Q3 2024 is CNY 15,262,038.49, down from CNY 76,016,071.12 in Q3 2023, indicating a decrease of about 80.0%[20]. - Total profit for Q3 2024 is CNY 16,407,540.33, compared to CNY 88,747,389.26 in Q3 2023, reflecting a decline of approximately 81.5%[20]. - The basic earnings per share for the period was ¥0.03, reflecting a 200.00% increase compared to the same period last year[3]. - The basic earnings per share for Q3 2024 is CNY 0.03, down from CNY 0.27 in Q3 2023, representing an 88.9% decrease[21]. - The total comprehensive income for Q3 2024 is CNY 9,895,697.17, compared to CNY 75,220,211.77 in Q3 2023, reflecting a decline of approximately 86.9%[21]. Research and Development - The company's R&D investment totaled ¥20,084,839.94, marking a 16.32% increase year-on-year[3]. - R&D expenses accounted for 16.65% of revenue, a decrease of 5.86 percentage points compared to the previous year[3]. - Total R&D investment for the year-to-date period is 35.81 million, influenced by one-time stock payment expenses related to the equity incentive for R&D personnel at the subsidiary Shui Mu Tian Peng[8]. - Research and development expenses rose to CNY 63,964,458.87, an increase of 35.7% compared to CNY 47,098,667.84 in the same period last year[19]. - Research and development expenses for the first three quarters of 2024 were CNY 23,706,591.21, compared to CNY 27,189,710.30 in 2023, reflecting a decrease of approximately 12.2%[27]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥5,537,631.05, which decreased by 96.69% year-on-year[3]. - Cash flow from operating activities for the first three quarters of 2024 is CNY 5,537,631.05, a decrease from CNY 167,359,458.96 in the same period last year[23]. - Cash flow from operating activities for the first three quarters of 2024 was CNY -15,857,578.47, compared to CNY 149,138,417.30 in the same period of 2023[30]. - The company incurred a total cash outflow from operating activities of CNY 249,058,212.73 in the first three quarters of 2024, compared to CNY 345,767,733.42 in the same period of 2023[30]. - The company's cash and cash equivalents decreased to CNY 439,770,777.33 from CNY 654,352,614.54, reflecting a decline of 32.7%[15]. - The cash and cash equivalents decreased by CNY 214,581,837.21 in Q3 2024, contrasting with an increase of CNY 302,485,717.55 in Q3 2023[23]. - The company reported cash and cash equivalents at the end of Q3 2024 of CNY 224,747,746.59, down from CNY 463,851,326.68 at the end of Q3 2023[31]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,286,920,354.07, a 1.12% increase from the end of the previous year[4]. - The total assets of the company reached CNY 2,286,920,354.07, a slight increase from CNY 2,261,496,123.25[16]. - Non-current assets totaled CNY 1,400,628,683.18, an increase of 6.5% from CNY 1,315,194,256.20[16]. - Total liabilities increased to CNY 239,985,661.37, up 9.7% from CNY 218,795,986.78[17]. - The company's total liabilities decreased to CNY 157,146,031.64 from CNY 185,645,431.89, showing a reduction of approximately 15.3%[26]. - The total equity increased to CNY 1,908,491,841.21 from CNY 1,897,486,726.10, marking a growth of about 0.5%[26]. Revenue and Costs - Total operating revenue for the first three quarters of 2024 was CNY 332,733,558.44, a decrease of 7.3% compared to CNY 358,927,163.10 in the same period of 2023[19]. - Total operating costs increased to CNY 308,284,008.90, up 11.1% from CNY 277,574,009.60 in the previous year[19]. - The cost of goods sold increased to CNY 83,640,604.16 from CNY 59,460,552.86, indicating a rise of about 40.5%[27]. - Sales revenue for the first three quarters of 2024 was CNY 226,355,067.57, a decrease of 50.9% compared to CNY 461,071,344.99 in the same period of 2023[30]. - The company reported a significant decrease in sales expenses, which fell to CNY 58,294,209.69 from CNY 127,116,617.06, a reduction of approximately 54%[27]. Investment Activities - Cash inflow from investment activities in Q3 2024 is CNY 564,296,968.41, compared to CNY 317,884,317.81 in Q3 2023, showing an increase of approximately 77.5%[23]. - Cash outflow from investment activities for Q3 2024 is CNY 749,459,270.85, up from CNY 160,286,286.95 in Q3 2023, indicating a significant increase of about 366.5%[23]. - Cash flow from investing activities in the first three quarters of 2024 was CNY -193,923,551.68, a significant decrease from CNY 160,903,994.15 in the previous year[30].